Establishment of a high level scientific research core according to European standards able to apply advanced technologies based on recombinant allergens in diagnosis, treatment and prevention of allergic diseases within OncoGen.

Development of competitive human resources for research by creating new jobs for postdoctoral researchers, PhD students and lab technicians.

Development of a new recombinant allergen-based diagnostic kit specific for ragweed allergic patients.

Ensuring the transfer of knowledge between academia and business.

Ensuring the transfer of project results to economy via two patents derived from the use of recombinant peptides, enabling the further development of tolerance induction in atopic patients to prevent allergic sensitization.

Promoting Qualitative Research by publishing 6 scientific papers on project results and submitting at least one project proposal within the Horizon 2020 programme during the 36 months of the project.